Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/new-haemophilus-influenzae-vaccine-licensed-3Xp5dYgpeV
References (0)
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- American Medical Association
- Copyright
- Copyright © 1988 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.1988.03720050003002
- Publisher site
- See Article on Publisher Site
Abstract
JUST AS QUESTIONS were being raised about the efficacy of the existing vaccine against Haemophilus influenzae disease, the Food and Drug Administration has licensed a new and much more immunogenic vaccine against the disease. It marks the first of a new generation of vaccines that, evidence indicates, provide much broader protection, even in infants, than do the existing vaccines against H influenzae type b. Furthermore, the conjugate vaccine holds out the promise of immunization against a number of other bacterial diseases of infancy. Unlike the current vaccine against H influenzae type b, which uses as the sole immunogen the capsular polysaccharide polyribosyl ribose phosphate, the polysaccharide in the new vaccine is linked to diphtheria toxoid. Such conjugated vaccines, as many studies over the past seven years have shown, effectively stimulate much higher antibody titers than polyribosyl ribose phosphate alone. In addition, also unlike the present vaccine, repeated doses of the
Journal
JAMA – American Medical Association
Published: Feb 5, 1988